中重度慢性肾脏病合并糖尿病患者的血糖评估中连续血糖监测指标的应用
研究纳入90例糖尿病合并CKD G3b至G5(非透析)患者,评估HbA1c与盲法连续血糖监测(CGM)指标的关系。结果显示GMI与HbA1c的相关性随CKD进展而减弱(G3b r=0.68,G4 r=0.52,G5 r=0.22),HbA1c与低血糖时间百分比及血糖变异系数无相关性。CGM指标可能作为HbA1c的辅助用于指导血糖管理,尤其在eGFR<30 ml/min/1.73 m2者。
要点
- GMI与HbA1c相关性随CKD进展减弱,G5期r=0.22且无统计学意义。
- HbA1c与TIR及高血糖时间百分比在G3b和G4期相关,但在G5期无相关。
- HbA1c与低血糖时间百分比及血糖变异系数在任何CKD分期均无相关。
核心结论
- CGM衍生的指标可能作为HbA1c监测的辅助,用于指导血糖管理,尤其在eGFR<30 ml/min/1.73 m2的患者中。
- 低血糖时间和血糖变异性是相关的血糖优化目标,而HbA1c未反映这些指标。
研究设计与样本
- 研究共纳入90例糖尿病合并CKD患者,其中G3b期33例、G4期43例、G5期(非透析)14例。
- 患者年龄均值±标准差为65.4±9.0岁,eGFR为26.1±9.6 ml/min/1.73 m2,HbA1c为7.4±0.8%。
- CGM指标通过盲法CGM(Medtronic Ipro2 with Enlite传感器)估算,并与同一周的HbA1c进行比较。
主要发现
- 葡萄糖管理指标(GMI)与HbA1c的相关性随CKD进展而减弱:G3b期r=0.68(P<0.0001),G4期r=0.52(P<0.001),G5期r=0.22(P=0.44),CKD分期间P=0.01。
- 在G3b和G4期,HbA1c与目标范围内时间(TIR,3.9-10.0 mmol/l)显著相关(r分别为-0.55和-0.54),与血糖>13.9 mmol/l的时间百分比显著相关(r分别为0.53和0.44),但在G5期无显著相关。
- HbA1c与血糖<3.0 mmol/l的时间百分比(r=-0.045,P=0.67)及变异系数百分比(CV)(r=-0.05,P=0.64)在任何CKD分期均无相关性。
- 仅eGFR是GMI与HbA1c差值偏倚的显著决定因素(eGFR每降低15 ml/min/1.73 m2,差值-0.28%,95% CI [-0.52 to -0.03],P=0.03)。
临床怎么用
- 作者认为,CGM衍生的指标可能作为HbA1c监测的辅助,用于指导血糖管理,尤其在eGFR<30 ml/min/1.73 m2的患者中。
- 作者指出,低血糖时间和血糖变异性是相关的血糖优化目标,而HbA1c未反映这些指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glycated hemoglobin A1c (HbA1c) has reduced reliability in advanced chronic kidney disease (CKD) owing to factors influencing red cell turnover. Recent guidelines support the use of continuous glucose monitoring (CGM) in glycemic assessment in these patients. We evaluated relationships between HbA1c and CGM metrics of average glycemia and glucose variability (GV) in moderate-to-advanced CKD. METHODS: There were a total of 90 patients with diabetes in CKD stages G3b (n = 33), G4 (n = 43), and G5 (nondialysis) (n = 14) (age [mean ± SD] 65.4 ± 9.0 years, estimated glomerular filtration rate [eGFR] 26.1 ± 9.6 ml/min per 1.73 m2, and HbA1c 7.4 ± 0.8%). CGM metrics were estimated from blinded CGM (Medtronic Ipro2 with Enlite sensor) and compared with HbA1c in the same week. RESULTS: Correlations between glucose management indicator (GMI) and HbA1c attenuated with advancing CKD (G3b [r = 0.68, P < 0.0001], G4 [r = 0.52, P < 0.001], G5 [r = 0.22, P = 0.44], P = 0.01 for CKD stage). In G3b and G4, HbA1c correlated significantly with time-in-range (TIR) (3.9-10.0 mmol/l) (r = -0.55 and r = -0.54, respectively) and % time > 13.9 mmol/l (r = 0.53 and r = 0.44, respectively), but not in G5. HbA1c showed no correlation with % time <3.0 mmol/l (r = -0.045, P = 0.67) or % coefficient of variation (CV) (r = -0.05, P = 0.64) in any CKD stage. Only eGFR was a significant determinant of bias for the difference between GMI and HbA1c (difference -0.28%, 95% CI [-0.52 to -0.03] per 15 ml/min per 1.73 m2 decrement, P = 0.03). CONCLUSION: CGM-derived indices might serve as an adjunct to HbA1c monitoring to guide glycemic management, especially in those with eGFR <30 ml/min per 1.73 m2. Time in hypoglycemia and glycemic variability are relevant glycemic targets for optimization not reflected by HbA1c.
引用
- Ling J, Ng JKCC, Lau ESH, et al. Continuous Glucose Monitoring Metrics in the Assessment of Glycemia in Moderate-to-Advanced CKD in Diabetes. Kidney Int Rep. 2022. PMID: 35685309. doi:10.1016/j.ekir.2022.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。